ESC 2026: Aficamten breaks new ground in nonobstructive HCM - Pharmaceutical Technology

Aficamten improves cardiac structure and diastolic function, strengthening its case as a targeted therapy for nonobstructive HCM. Aficamten improves cardiac structure and diastolic function, strengthening its case as a targeted therapy for nonobstructive HCM. Results from the ACACIA-HCM trial with Cytokinetics’s Myqorzo (aficamten) could strengthen the drug’s differentiation within the evolving HCM treatment landscape. Image credit: [Michael Vi]/Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in the…

Source: Pharmaceutical Technology